Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960108 | 0.80 | ABL1 (0.48) | ABL1RAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL24956359 | 0.80 | NPC1 (0.52) | ABL1RAB9AGRM5NPC1SMN1; SMN2 | |
| SCHEMBL24958916 | 0.80 | ABL1 (0.53) | ABL1RAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL24956358 | 0.77 | NPC1 (0.56) | ABL1RAB9ANPC1SMN1; SMN2TSHR | |
| SCHEMBL24956354 | 0.74 | SMYD3 (0.51) | HPGDABL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24960094 | 0.74 | NPC1 (0.48) | HPGDABL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24958860 | 0.72 | ABL1 (0.45) | HPGDABL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13555876 | 0.69 | MAP4K4 (0.56) | ABL1RAB9AGRM5NPC1TDP1 | |
| SCHEMBL25912408 | 0.69 | CNR1 (0.56) | HPGDABL1RAB9AGRM5NPC1 | |
| SCHEMBL19445899 | 0.67 | NPC1 (0.56) | HPGDRAB9ANPC1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | GAA 1038/4885MAPT 3314/4885HPGD 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.